Laboratory Evidence to Support the Use of Long-Term Adjuvant Tamoxifen Therapy for Breast Cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Animal models all demonstrate that tamoxifen is tumouristatic in the case of breast tumours and long-term or indefinite therapy is required to prevent the appearance of tumours. When treatment is stopped, tumours appear spontaneously or can be encouraged to re-appear with oestrogen therapy. These data support the view that adjuvant clinical trials with tamoxifen should employ a 5- or 10-year treatment regimen.

Related collections

Author and article information

Journal

Journal ID (publisher-id): HRE

Journal ID (doi): 10.1159/issn.0018-5051

Title: Hormone Research in Paediatrics

Publisher: S. Karger AG

ISBN: 978-3-8055-5105-2

ISBN: 978-3-318-01977-3

ISSN (Print): 0018-5051

ISSN (Electronic): 2571-6603

Publication date Subscription-year: 1989

Publication date (Print): 1989

Publication date (Electronic): 02 December 2008

Volume: 32

Issue: Suppl 1

Pages: 261-265

Affiliations

Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison, Wisc. USA

Article

Publisher ID: 181360 Other ID: Horm Res 1989;32:261–265

DOI: 10.1159/000181360

SO-VID: a5246ecf-6305-40b3-9b4a-1f764a19e23e

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Call for Papers: Epidemiology and Health Impacts of Neuroendocrine Tumors

Submit here before August 30, 2024

Laboratory Evidence to Support the Use of Long-Term Adjuvant Tamoxifen Therapy for Breast Cancer

Read this article at

Abstract

Related collections

Karger: Endocrinology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 292